vs
CANTALOUPE, INC.（CTLP）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是CANTALOUPE, INC.的1.8倍（$139.1M vs $78.7M），VERACYTE, INC.净利率更高（20.6% vs -0.1%，领先20.7%），VERACYTE, INC.同比增速更快（21.5% vs 6.8%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 7.7%）
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
CTLP vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.8倍
$78.7M
营收增速更快
VCYT
高出14.7%
6.8%
净利率更高
VCYT
高出20.7%
-0.1%
两年增速更快
VCYT
近两年复合增速
7.7%
损益表 — Q2 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $78.7M | $139.1M |
| 净利润 | $-70.0K | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | 2.0% | 16.3% |
| 净利率 | -0.1% | 20.6% |
| 营收同比 | 6.8% | 21.5% |
| 净利润同比 | -101.4% | — |
| 每股收益（稀释后） | $0.00 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTLPVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $78.7M | $140.6M | ||
| Q3 25 | $80.9M | $131.9M | ||
| Q2 25 | $82.6M | $130.2M | ||
| Q1 25 | $75.4M | $114.5M | ||
| Q4 24 | $73.7M | $118.6M | ||
| Q3 24 | $70.8M | $115.9M | ||
| Q2 24 | $72.7M | $114.4M |
净利润CTLPVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $-70.0K | $41.1M | ||
| Q3 25 | $-919.0K | $19.1M | ||
| Q2 25 | $6.8M | $-980.0K | ||
| Q1 25 | $49.2M | $7.0M | ||
| Q4 24 | $5.0M | $5.1M | ||
| Q3 24 | $3.6M | $15.2M | ||
| Q2 24 | $2.2M | $5.7M |
毛利率CTLPVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率CTLPVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 2.0% | 26.4% | ||
| Q3 25 | 2.0% | 17.4% | ||
| Q2 25 | 6.3% | -4.0% | ||
| Q1 25 | 9.1% | 2.5% | ||
| Q4 24 | 8.4% | 3.5% | ||
| Q3 24 | 5.8% | 10.4% | ||
| Q2 24 | 4.9% | 4.0% |
净利率CTLPVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | -0.1% | 29.3% | ||
| Q3 25 | -1.1% | 14.5% | ||
| Q2 25 | 8.3% | -0.8% | ||
| Q1 25 | 65.2% | 6.2% | ||
| Q4 24 | 6.7% | 4.3% | ||
| Q3 24 | 5.0% | 13.1% | ||
| Q2 24 | 3.0% | 5.0% |
每股收益（稀释后）CTLPVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.00 | $0.50 | ||
| Q3 25 | $-0.02 | $0.24 | ||
| Q2 25 | $0.10 | $-0.01 | ||
| Q1 25 | $0.65 | $0.09 | ||
| Q4 24 | $0.07 | $0.07 | ||
| Q3 24 | $0.04 | $0.19 | ||
| Q2 24 | $0.03 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.0M | $439.1M |
| 总债务越低越好 | $37.7M | — |
| 股东权益账面价值 | $252.5M | $1.3B |
| 总资产 | $381.9M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资CTLPVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $53.0M | $362.6M | ||
| Q3 25 | $55.0M | $315.6M | ||
| Q2 25 | $51.1M | $219.5M | ||
| Q1 25 | $46.3M | $186.1M | ||
| Q4 24 | $27.7M | $239.1M | ||
| Q3 24 | $33.1M | $274.1M | ||
| Q2 24 | $58.9M | $235.9M |
总债务CTLPVCYT
| Q1 26 | — | — | ||
| Q4 25 | $37.7M | — | ||
| Q3 25 | $38.3M | — | ||
| Q2 25 | $38.7M | — | ||
| Q1 25 | $39.2M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $37.3M | — | ||
| Q2 24 | $37.5M | — |
股东权益CTLPVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $252.5M | $1.3B | ||
| Q3 25 | $251.8M | $1.3B | ||
| Q2 25 | $251.0M | $1.2B | ||
| Q1 25 | $240.7M | $1.2B | ||
| Q4 24 | $190.1M | $1.2B | ||
| Q3 24 | $186.2M | $1.2B | ||
| Q2 24 | $181.7M | $1.1B |
总资产CTLPVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $381.9M | $1.4B | ||
| Q3 25 | $389.5M | $1.4B | ||
| Q2 25 | $381.9M | $1.3B | ||
| Q1 25 | $370.5M | $1.3B | ||
| Q4 24 | $303.0M | $1.3B | ||
| Q3 24 | $312.1M | $1.3B | ||
| Q2 24 | $335.6M | $1.2B |
负债/权益比CTLPVCYT
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $-614.0K | — |
| 自由现金流率自由现金流/营收 | -0.8% | — |
| 资本支出强度资本支出/营收 | 4.8% | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | $25.8M | — |
8季度趋势，按日历期对齐
经营现金流CTLPVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $3.1M | $52.6M | ||
| Q3 25 | $7.0M | $44.8M | ||
| Q2 25 | $9.4M | $33.6M | ||
| Q1 25 | $22.4M | $5.4M | ||
| Q4 24 | $522.0K | $24.5M | ||
| Q3 24 | $-12.0M | $30.0M | ||
| Q2 24 | $14.3M | $29.6M |
自由现金流CTLPVCYT
| Q1 26 | — | — | ||
| Q4 25 | $-614.0K | $48.8M | ||
| Q3 25 | $3.5M | $42.0M | ||
| Q2 25 | $4.3M | $32.3M | ||
| Q1 25 | $18.6M | $3.5M | ||
| Q4 24 | $-3.8M | $20.4M | ||
| Q3 24 | $-15.8M | $27.7M | ||
| Q2 24 | $8.5M | $26.8M |
自由现金流率CTLPVCYT
| Q1 26 | — | — | ||
| Q4 25 | -0.8% | 34.7% | ||
| Q3 25 | 4.4% | 31.8% | ||
| Q2 25 | 5.3% | 24.8% | ||
| Q1 25 | 24.6% | 3.1% | ||
| Q4 24 | -5.1% | 17.2% | ||
| Q3 24 | -22.3% | 23.9% | ||
| Q2 24 | 11.7% | 23.4% |
资本支出强度CTLPVCYT
| Q1 26 | — | — | ||
| Q4 25 | 4.8% | 2.7% | ||
| Q3 25 | 4.2% | 2.1% | ||
| Q2 25 | 6.2% | 1.0% | ||
| Q1 25 | 5.1% | 1.6% | ||
| Q4 24 | 5.8% | 3.5% | ||
| Q3 24 | 5.4% | 1.9% | ||
| Q2 24 | 7.9% | 2.4% |
现金转化率CTLPVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | 1.38× | — | ||
| Q1 25 | 0.46× | 0.76× | ||
| Q4 24 | 0.10× | 4.80× | ||
| Q3 24 | -3.36× | 1.98× | ||
| Q2 24 | 6.47× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
